Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D. Scott, Michael W. Miller, Duane E. DeMong et al.|Journal of Medicinal Chemistry|2017Cited by 147
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer’s DiseaseShawn J. Stachel, John J. Renger, Sokreine Suon et al.|Journal of Medicinal Chemistry|2016Cited by 49